Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes mellitus (T2DM) given their extra-pancreatic effects. However, there are concerns about carcinogenesis in the pancreas and thyroid gland. We aimed to evaluate the site-specific...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Korean Diabetes Association
2025-01-01
|
| Serie: | Diabetes & Metabolism Journal |
| Soggetti: | |
| Accesso online: | http://e-dmj.org/upload/pdf/dmj-2024-0105.pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|